Abstract 171P
Background
To evaluate the prognostic value of prognostic nutritional index(PNI)in esophageal cancer patients under minimally invasive esophagectomy (MIE) with peritoneal metastasis.
Methods
The clinical and pathological data of 197 patients under MIE with anastomotic leakage from January 2013 to December 2015 were analyzed retrospectively.
Results
PNI was not associated with various clinicopathological factors such as age, gender, smoking history, tumor location, tumor length, differentiation degree, T stage, N stage, treatment mode, TNM stage and lymph node metastasis rate (P > 0.05). Univariate survival analysis showed that male, smoking history, advanced tumor stage, tumor length>5cm, advanced N stage, higher lymph node metastasis rate, advanced TNM stage, and treatment modality were associated with poor prognosis. Multivariate analysis showed that N stage (HR = 6.108, CI:1.614-23.113, P = 0.008) and treatment modality (HR = 0.362, CI: 0.213-0.617, P < 0.001) are independent risk factors. PNI is not an independent risk factor.
Conclusions
Prognostic nutritional index is not an independent risk factor of the prognosis for patients under minimally invasive esophagectomy with anastomotic leakage. Treatment method and lymph node metastasis are still the main factors affecting long-term survival in this group.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The 4th Hospital of Hebei Medical University.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
314P - An EGF motif of Del1 inhibits efficient angiogenesis and suppresses tumour growth in vivo
Presenter: Hisataka Kitano
Session: Poster display session
Resources:
Abstract
315P - Inhibition of JAK1 sensitizes human head and neck cancer cells to cetuximab
Presenter: James Bonner
Session: Poster display session
Resources:
Abstract
316TiP - Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study
Presenter: Ezra Cohen
Session: Poster display session
Resources:
Abstract
322P - Three-year overall survival update from the PACIFIC trial
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract
323P - Novel tumour mutation score versus tumour mutation burden in predicting survival after immunotherapy in pan-cancer from MSK-IMPACT cohort
Presenter: Yuan Li
Session: Poster display session
Resources:
Abstract
324P - A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy
Presenter: Tsu Yi Chao
Session: Poster display session
Resources:
Abstract
325P - Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma
Presenter: Lawrence Wong
Session: Poster display session
Resources:
Abstract
326P - Autologous V gamma 9 V delta 2 T cell therapy to target Epstein Barr Virus (EBV)-related malignancies
Presenter: Esdy Rozali
Session: Poster display session
Resources:
Abstract
327P - Neoantigen profile of hepatocellular carcinoma reveals its correlation with tumour progression and clonal evolution
Presenter: Xiaolong Liu
Session: Poster display session
Resources:
Abstract
328P - A retrospective analysis of patients with non-small cell lung cancer who developed drug-induced lung disorder by immune checkpoint inhibitors
Presenter: Fumiko Hayashi
Session: Poster display session
Resources:
Abstract